Cargando…
ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells
BACKGROUND: ZNF217 is a candidate oncogene located at 20q13, a chromosomal region frequently amplified in breast cancers. The precise mechanisms involved in ZNF217 pro-survival function are currently unknown, and utmost importance is given to deciphering the role of ZNF217 in cancer therapy response...
Autores principales: | Thollet, Aurélie, Vendrell, Julie A, Payen, Léa, Ghayad, Sandra E, Ben Larbi, Sabrina, Grisard, Evelyne, Collins, Colin, Villedieu, Marie, Cohen, Pascale A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996367/ https://www.ncbi.nlm.nih.gov/pubmed/21059223 http://dx.doi.org/10.1186/1476-4598-9-291 |
Ejemplares similares
-
Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer
por: Bellanger, Aurélie, et al.
Publicado: (2021) -
The Intricate Interplay between the ZNF217 Oncogene and Epigenetic Processes Shapes Tumor Progression
por: Fahmé, Pia, et al.
Publicado: (2022) -
The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value
por: Cohen, Pascale A., et al.
Publicado: (2015) -
Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer
por: Vendrell, Julie A., et al.
Publicado: (2019) -
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer
por: Vilquin, Paul, et al.
Publicado: (2015)